Negotiating a Policy of Prudent Science and Proactive Law in the Brave New World of Genetic Information by Chen, Sherwin
Hastings Law Journal
Volume 53 | Issue 1 Article 4
1-2001
Negotiating a Policy of Prudent Science and
Proactive Law in the Brave New World of Genetic
Information
Sherwin Chen
Follow this and additional works at: https://repository.uchastings.edu/hastings_law_journal
Part of the Law Commons
This Note is brought to you for free and open access by the Law Journals at UC Hastings Scholarship Repository. It has been accepted for inclusion in
Hastings Law Journal by an authorized editor of UC Hastings Scholarship Repository. For more information, please contact
wangangela@uchastings.edu.
Recommended Citation
Sherwin Chen, Negotiating a Policy of Prudent Science and Proactive Law in the Brave New World of Genetic Information, 53 Hastings
L.J. 243 (2001).
Available at: https://repository.uchastings.edu/hastings_law_journal/vol53/iss1/4
Negotiating a Policy of Prudent
Science and Proactive Law in the





In the waiting room of an obstetrician's office, Lisa and Rick, a
couple in their late 30's, anxiously await the results of an
amniocentesis test.' Lisa is in the 16th week of what may be her last
viable pregnancy. She previously postponed having children in favor
of establishing a career for herself and developing a healthy
relationship with her second husband. The procedure she awaits
requires extraction of a small amount of amniotic fluid, a clear liquid
teeming with fetal cells that may be analyzed at a lab.2 Lisa's test
results are the fruit of a powerful prenatal diagnostic technique that
can, with a high degree of reliability, ascertain the sex of the child and
indicate whether the fetus might be afflicted with one of over 80
genetically based metabolic disorders.' While their particular
amniocentesis results may only test for three or four genetic diseases,
Lisa and Rick may choose to seek limited intrauterine treatment or
* B.S., Stanford University, 1996; M.S., Rensselaer Polytechnic Institute, 1997; J.D.
Candidate, University of California, Hastings College of the Law, 2002. I am grateful to
Professors Liu, Winner, and McGinn for their constructive insights on various drafts of
this note. I also thank my friends at Cooley Godward, Howrey Simon, and Russo & Hale
for their invaluable contributions to my legal training and education. I am fortunate to
have received the support and encouragement of James Chen, Sophia Lau, and Connie
Yang throughout the writing process. Finally, I dedicate this note in memory of my
mother, whose strength and courage in the face of medical challenges continues to inspire
me to overcome many of life's challenges.
1. See generally American Academy of Pediatrics - Committee on Genetics, Prenatal
Diagnosis for Pediatricians, 84 PEDIATRICS 741 (1989).
2. Id. at 742.
3. Id. at 741-742.
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termination of the pregnancy based on this information. Although
this medical technology was developed and first applied less than
forty years ago, it is already considered a common element of medical
practice.4
As the above vignette suggests, the fruits of genetic research
have enabled doctors to estimate childrens' chances for developing
hundreds of types of diseases, some of them fatal. Other technologies
include new identification techniques (witness the use of polymerase
chain reaction techniques during the O.J. Simpson trial), medical
diagnostics, limited therapies, and even the development of new
forms of life through genetic recombination. With these
unprecedented and powerful new possibilities, it is clear that the legal
dimensions of genetic research and related technologies must be
carefully examined.
This note seeks to analyze the social and legal issues that result
from the research, development, and deployment of genetic
information technologies (hereinafter "GITs") that provide us with
increasingly more information about our genetic make-up. In part
one of this note, I develop a general treatment of the issues unique to
GITs. In part two, I trace policy concerns and outline a paradigm of
improved education, discussion, and law that I believe must
ultimately contribute towards more democratic lawmaking in genetic
research and technology development. As Robert Proctor, a scholar
studying the politics of cancer, announces, "ours has been heralded-
perhaps with some hyperbole-as the Age of Genes."5
I. General Overview of Major Issues
The majority of current genetic research applications consist of
diagnostic techniques that can provide detailed information about an
individual's genetic makeup. However, because the successful
identification of the "gene for" a condition is rarely concurrent with
the development of a treatment for that condition, most techniques
derived from genetic research are extremely limited in a therapeutic
capacity.6 There are only a dozen or so active gene therapy protocols
worldwide, and experts agree that use of such is limited to relatively
rare disorders, is very expensive, and requires special expertise.
4. For a discussion of alternative genetic diagnostic tests such as chorionic villi
sampling (CVS) and maternal serum alpha-fetoprotein sampling, see David T. Morris,
Cost Containment and Reproductive Autonomy: Prenatal Genetic Screening and the
American Health Security Act of 1993,20 AM. J. L. & MED. 295,296-97 (1994).
5. ROBERT V. PROCTOR, CANCER WARS: How POLITICS SHAPES WHAT WE
KNOW AND DON'T KNOW ABOUT CANCER 217 (1995).
6. See Denise K. Casey, What Can the New Gene Tests Tell Us?, JUDGES' J., Summer
1997,at 14, 15.
7. Benjamin P. Sachs & Bruce Korf, The Human Genome Project: Implications for
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Furthermore, the most reliable diagnoses returned by genetic testing
often indicate the need for prophylactic coloectomy, ovariectomy, or
mastectomy.8 In some cases, genetic testing can only reveal the
likelihood of an incurable condition (e.g., Huntington's disease).9
This scarcity of successful genetic treatments is known as the
"therapeutic gap."" Thus, the primary use of genetic research has
been as an information technology. In the near future, it is likely that
we will continue to develop a science that will provide more precise
indicators of our genetic fate, but do little to enhance our capability
to control that trajectory. Even without the ability to directly
intervene in the genetic course of human beings, there are still many
legal implications to be discussed.
A. Genetic Information and the Specter of Eugenics
The modem collection and organization of genetic information
in the United States is based in the National Center for Human
Genome Research, established by the National Institutes of Health
(NIl) on October 1, 1989." The Human Genome Initiative (HGI)
was approved shortly afterward by Congress in 1990.2 Today, HGI is
jointly implemented by the NIH and Department of Education." Its
goal is to map and sequence the entire human genome, an
undertaking projected to require fifteen years for completion.'4 The
ultimate goal of the project is to characterize all of the more than
50,000 human genes for further biological study.'5 James D. Watson,
Ph.D., co-discoverer of the DNA double helix and former director of
the Human Genome Initiative, believes the HGI contributes to the
"public good in the best sense" by helping to "assist biomedical
researchers in their assault on disease.' 6  Benjamin Sachs, an
obstetrician studying the implications of the HGI, predicts that the
"Genome Project will have a greater impact on medical practice than
any previous contribution to medical research."' At the time of this
writing, more than 3,000 medical disorders resulting from a single
the Practicing Obstetrician, 81 OBSTETRICS AND GYNECOLOGY 458,460 (1993).
8. See generally id.
9. See generally Eric T. Juengst, The Ethics of Prediction: Genetic Risk and the
Physician-Patient Relationship, 1 GENOME SCI. & TECH. 30 (1995).
10. See id.
11. See Sachs & Korf, supra note 7, at 458.
12- See iL
13. Human Genome Project Information, available at http:l/www.ornl.gov/hgmis/ (last
modified Aug. 28, 2001).
14. Id.
15. Id.
16. Richard M. Glass MD, AAAS Conference Explores Ethical Aspects of Large
Pedigree Genetic Research, 267 JAMA 2158 (1992).
17. Sachs & Korf, supra note 7, at 458.
gene disruption have been catalogued, and new genetic disorders are
discovered almost monthly.'8
The stated goals of HGI seem noble and admirable. Many
scientists argue that the HGI is essential for solidifying the foundation
of modem biology and medicine, as well as for furthering the
understanding of human genetics and the development of viable
medical applications."9 The European counterpart to HGI is the
Human Genome Organization (HGO), founded in 1988.20 What goes
unspoken, however, is that projects like the HGI and HGO can also
serve as government-funded and administered genetic databases of
the human genetic formula. The information provided by the HGI
and current genetic diagnostic techniques is sensitive and could
conceivably be used for a variety of purposes. Who should have
access to and control over genetic information? Furthermore, the
HGI will create a complete database of human genetic information.
This genetic database can be accessed to determine what it means to
be a "normal" human being. Who will have the authority to
determine what is normal and what is sub-standard? What will form
the basis for these judgments?
Thus, concern over privacy rights regarding who shall have
access to genetic information and eugenics and who shall determine
the genetic choices, have achieved escalating attention as the science
of genetics has matured. Today, the focus on genetic information has
shifted away from hypothetical moral questions to more practical,
legal concerns. The American Association for the Advancement of
Science (AAAS) held an interdisciplinary conference in 1992 to
discuss the legal implications of the Human Genome Project."' They
predicted that any arising conflicts would involve three basic issues:
"1) a core of self-identity-heightening concerns about privacy and
confidentiality; 2) the potential to predict an individual's future; and
3) implications extending beyond the individual to family members
and even potential family members."
Increasingly sophisticated and reliable information from genetic
diagnostic tests presents a dilemma of information and privacy rights.
As researchers continue to make progress in deciphering the human
genetic code, more and more genetic information will become
available. Who should control the release of such information?
Furthermore, who should know the results of the genetic test? What
diseases should be disclosed using genetic tests? Questions like these
18. Id. at 459.
19. Id. at 458.
20. Id. at 458-459.
21. Glass, supra notel6.
22- Id.
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make it clear that the use and release of genetic information must be
carefully studied.
B. Studying the Legal Implications of Genetic Information Technologies
Recent genetic research has reaped the benefits of some federal
study. In the United States, the Department of Energy (DOE) and
the National Institute of Health (NIH) have collectively designated
five million dollars per year to the National Center for Human
Genome Research (NCHGR) for "the study of ethical, legal, and
social issues raised by the clinical application of new genetic
information, an unprecedented public investment."' The NCHGR
committee sponsored by the DOE and NIH is known as ELSI: the
Ethical, Legal, and Social Implications Program, housed within the
HGI.24 Consequently, the official mandate of ELSI is to anticipate
problems resulting from continuing advances in genetic technology,
educate the public about genetics, and develop policies to guide its
use.2
The NIH and the DOE allocate, 5% and 3% respectively, of
their genome budgets to ELSI, representing the first and largest
federally supported program devoted to research of bioethical issues
raised by ongoing research.26 Similar groups include the Ad Hoe
Committee on Insurance Issues in Genetic Testing, formed by the
American Society of Human Genetics (an academic group) in 1991.7
The Genetics Research Group of the Hastings Center Institute of
Society, Ethics, and the Life Sciences is another "interdisciplinary
task force of people with academic training in law, medicine,
philosophy, theology, biology, genetics, and the social sciences, [that]
has been considering many of these questions for more than twenty
years." 28 Similarly, there are numerous universities and organizations
around the country sponsoring programs related to bioethics and the
Human Genome Initiative; enough for any respectable science and
technology. But are such groups effective in safeguarding the proper
release and use of genetic information? Recent developments in the
23. Juengst, supra note 9, at 30.
24. Eric T. Juengst, Human Genome Research and the Public Interest. Progress Notes
from an American Science Policy Experiment, 54 THE AM. J. OF HUMAN GENETICS 121,
122 (1994).
25. Id
26. Lisa S. Parker, Bioethics for Human Geneticists: Models for Reasoning and
Methods for Teaching, 54 THE AM. J. OF HUMAN GENETICS 137, 138 (1994).
27. Id
28. Tabitha M. Powledge & John Fletcher, Guidelines for the Ethical, Social, and
Legal Issues in Prenatal Diagnosis: A Report From the Genetics Research Group of the
Hastings Center, Institute of Society, Ethics, and the Life Sciences, 300 NEW ENG. J. MED.
168, 169 (1979).
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deployment of genetic technologies suggest the answer is no.
Current genetic research is advancing rapidly and medical
applications are not far behind. "With the development of the first
detailed index and reference marker maps of the human genome, the
pace of gene localization and subsequent diagnostic and predictive
test development is accelerating dramatically." 9 And yet, the nature
of genetic information, as it relates to humans, is completely unique
and unprecedented in the field of medicine.' This innovative data
could affect serious scientific, commercial, and social changes.3' For
instance, genetic research on severe mental disorders such as
schizophrenia and Huntington's Disease raises several unique legal
questions about patient discrimination and fair treatment. Primary
concerns include the protection of confidential research data and the
establishment of proper research protocols that protect subject health
and privacy and reduce risk.32 Since these mental diseases reduce
mental competency and impair decision-making abilities, researchers
and clinicians face a different sort of dilemma. They must contend
with assessing mental competency and informed consent, as well as
evaluating the legal and competent transference of substituted
judgment for subjects with compromised mental ability.33 In addition,
there is great potential for discrimination against these patients if
their genetic susceptibility is disclosed.' Many neurological disorders
such as Huntington's disease show a Mendelian pattern of inheritance
with high penetrance, meaning that individuals found to be at risk
through genetic tests are extremely likely to develop the disorder.35
Consider also the recent implication of the MSH2 gene in colon
cancer, which was immediately followed by efforts to develop a
diagnostic screening application. About "one in 200 Americans is
suspected of harboring the gene, which confers a 70 to 90 percent risk
of colon cancer and a number of other malignancies over the lifetime
of the carrier. 3 6 The development of a diagnostic technique would
have profound social and health-care policy ramifications. Once
identified, what would happen to those diagnosed with the colon
cancer gene? Lacking any effective treatment to eradicate colon
29. Juengst, supra note 9, at 23 (Quoting Cooper, DN, & Schmidtke, Molecular genetic




32. See David Shore et al., Legal and Ethical Issues in Psychiatric Genetic Research, 48
AM. J. OF MED. GENETICS (NEUROPSYCHIATRIC GENETICS), 17,17 (1993).
33. Id.
34. Id.
35. Id. at 19.
36. PROCTOR, supra note 5, at 237.
[Vol. 53
November 2001] GENETIC INFORMATION TECHNOLOGIES
cancer, would those diagnosed with the gene simply be handed a
death sentence? What would insurers and employers think of these
people? And what of the children who carry the gene but have not
manifested any symptoms? There is no telling how their lives might
be affected. Currently, there are no clearly structured policies to
judiciously control the release of this kind of information.
Similarly, the development of breast cancer detection techniques
is an indicator of future legal quandaries. Recently, the BRCA1 and
BRCA2 genes were implicated in female breast cancer.' Already, a
diagnostics firm from Gaithersburg, Maryland, has announced plans
to commercialize diagnostic tests that would contribute to a database
to provide genetic risk profiles to the health-care community."
OncoMed, Inc., plans to use the medical records of the Cancer Family
Genetic Database compiled by the Hereditary Cancer Institute of
Omaha, Nebraska." This database contains the records of more than
200,000 people from 2,300 cancer families throughout the world."
Accessing such a vast, global database for commercial purposes raises
serious legal questions. How will privacy be maintained? Is it legal to
put the genetic code of a person up for sale? These concerns remain
unanswered even as research, development, and use of GITs
continue.
Genetic applications have developed so quickly that many
clinicians find themselves in the position of having powerful
information but no established program or protocol with which to
adequately communicate this information to the patient. Further
pressure is placed upon the clinician because genetic information can
often have a very significant effect on important decisions, such as
planning for children.4 ' Again, these issues are unique to genetic
diseases. The technology to diagnose is less of an issue than the legal
framework to deal with the questions raised by the release of genetic
information.
The National Advisory Council (NAC) for the Human Genome
Research Project tamely responded to possible infringement of
privacy rights by commenting that it was "premature to offer DNA
testing or screening for cancer predisposition outside a carefully
monitored research environment. ' '42  Unfortunately, while
independent groups that examine and discuss social and legal issues
do exist, they can do little more than suggest possible guidelines for
GIT use, and do not appear to be effective in providing a unified,




41. See generally Juengst, supra note 9, at 22.
42. PROCTOR, supra note 5, at 239.
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effective policy for regulating the release of genetic information.
Given the sizable profits that may result from such tests and
information, commercial development may be difficult to slow. Less
than two years after the cloning of BRCA1, a legal dispute over who
owns the property rights to the gene was filed.'3 Examples of this
kind demonstrate how the unique nature of genetic technologies
makes it tempting to brush aside legal considerations in the rush to
develop profitable medical applications.
C. Genetic Discrimination
The term "genetic discrimination" has been coined by many
academics to describe the possibility of social, economic, and political
discrimination against individuals who have been diagnosed with
genetic disorders. 44 Accordingly, Professor Paul Billings, a geneticist,
is wary of how genetic applications can highlight differences in social
populations:
Social, political, and economic changes in the United States have
encouraged the notion that the origin of difference is biological or
genetic .... By promoting the idea that human traits are genetic
and amenable to scientific analysis-ideas and approaches which
emphasize difference-the determinative nature of such traits is
highlighted, and social or political parties are relieved of
responsibility. The outcome .... is unequal treatment of groups
justified by their biological variation, and the socio-political
absolution of injustice, ignorance, fear or social/political failures as
causal.45
An example of such treatment occurred in December of 1992,
when the Centers for Disease Control and Prevention explained that
a high percentage of breast cancer in a certain US urban city was the
result of an excessive concentration of Jewish residents there. 6 At
the time, people of Jewish descent were believed to have higher rates
of breast cancer than other Americans.47 In this case, genetic data has
been used to explain away the presence of cancer clusters by placing
43. Id.
44. Genetic discrimination has been defined as "discrimination against an individual
or against members of that individual's family solely because of real or perceived
differences from the 'normal' genome in the genetic constitution of the individual."
George P. Smith II, Accessing Genomic Information or Safeguarding Genetic Privacy, 9
J.L. & HEALTH 121, 124 (1994-95) (quoting Marvin R. Natowicz et al., Genetic
Discrimination and the Law, 50 AM. J. HUM. GENETICS 465, 466 (1992)).
45. Paul Billings, Genetic Discrimination and Behavioural Genetics: The Analysis of
Sexual Orientation, INTRACTABLE NEUROLOGICAL DISORDERS, HUMAN GENOME
RESEARCH AND SOCIETY: PROCEEDINGS OF THE THIRD INTERNATIONAL BIOETHICS
SEMINAR IN FUKUI 38 (1993).
46. See PROCTOR, supra note 5, at 241.
47. Id.
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blame on ethnic predispositions.
The hereditary nature of genetics also means that information
from diagnostic tests almost always pertains to family members as
well as the individual. If a patient is diagnosed as a carrier, another
relative may also have a high chance of being a carrier.' The
hereditary nature of genetic diseases sometimes means that the
individual's parents, siblings, and potential offspring are all at risk.
Should parents have the right to test their children for genetic
diseases? As discussed earlier, tests can predict the chances a child
may develop Huntington's Disease, but tests offer no cure." Could
knowledge of the possibility of manifesting the disease actually
detract from the child's quality of life more than the disease itself?
Inevitably, difficult issues of patient confidentiality and professional
responsibilities arise. Juengst asks, "If the patient decides not to warn
relatives about their common risks, does the professional have an
obligation to do so? ... The question is, how far into the gene pool do
the geneticist's professional obligations go?"50
In his Editor's introduction to Juengst's article, Michael Yesley
contends that "genetic information will play a central role in health
care, but [it] may destroy individuals' self-esteem and be used to
discriminate against them."'" Genetic information has often been
cited to justify discriminatory and sometimes bizarre behavior. For
example, research data from the HGI is cited in Germany where
sexual variation has been "treated" by psychosurgery and hormone
injections.52 Behavioral genetic research from the United States is
used to justify eugenic policies and legislation in Malaysia and
Singapore.53  Similarly, electro-convulsive therapy is used on
homosexual men in China, a "treatment" which may have found its
inspiration in Western behavioral genetic research.' Here in the
United States, screening for sickle-cell anemia, a condition of fatigue
and weariness due to improperly developed red blood cells, was
correlated with employer discrimination." Given these global effects,
some scientists recommend "the embargoing of research results and
ending scientific collaborations ... until adverse practices arising
48. See Technological Advances in Genetic Testing: Implications for the Future, 1996:
Hearing Before the Subcomm. on Tech. of the House Comm. on Science, 104th Cong. 79
(1996) (statement of Karen Rothenberg, Director, Law & Health Care Program,
University of Maryland School of Law).
49. See Lynn Ludlow, For Genetic Honesty, S.F. EXAMINER, Sept. 27, 1994, at A14.
50. Juengst, supra note 9, at 26.
51. Id. at 21.





from defining a normal, human trait as a 'biological entity,' a 'disease'
or 'illness' ceases."56  In part two, I discuss whether a general
moratorium on genetic research is necessary.
D. Genetic Determinism and the Uncertain Fortune Cookie
The perceived infallibility of genetic information has engendered
a sense of fatalism in those families diagnosed with a genetic
condition: "If the demon seed of cancer followed an unalterable
course from parent to offsying, what were physicians to tell the
children of cancer victims?" In truth, many genetic diseases have a
genetic component as well as an environmental influence." As with
almost all conditions that have a genetic basis, environmental factors
and chance are significant, if not equal determinants of
susceptibility. 9 This means that environmental factors can speed or
slow the onset of a disease or condition that is genetically predicted.
60
An overemphasis on genetics and assignment of blame to the biology
of the individual is imprudent. For, "Carcinogens work on
predispositions, but this should not overshadow the fact that the
majority of cancers are environmentally induced and therefore
preventable."'" Furthermore, even though a disorder may be strongly
influenced by a single gene, the outcome will also depend on
interactions with other genes and hormones inside the cell.62 The
public must be made acutely aware of the conditional nature of most
genetic information. Current applications are sometimes inaccurate,
reflecting the limitations of genetic science, which deals in statistics
and probabilities, and not certainties:
Yet genetic susceptibility testing will introduce a perhaps
heretofore unprecedented level of uncertainty into medical practice.
If, in the pursuit of health, women are exposed to decades of
uncertainty during which they anxiously await the fulfillment of
some, not yet understood, genetic destiny.... Then the wonder,
power, immediacy and seeming clarity of genetic technology may
begin to appear more in the guise of Pandora's Box than the Holy
Grail.63
The conditional nature of information provided by genetic tests
56. Id.
57. PROCrOR, supra note 5, at 220.
58. See Janet Basu, Genetic Roulette, STANFORD, Nov./Dec. 1996, at 36,43.
59. See Eric Mills Holmes, Solving the Insurance/Genetic Fair/Unfair Discrimination
Dilemma in Light of the Human Genome Project, 85 KY. L.J. 503, 522 (1996-97).
60. See Basu, supra note 58, at 43.
61. PROCrOR, supra note 5, at 243.
62. See Basu, supra note 58, at 43.
63. Nancy Press, Genetic Testing for Breast Cancer: Women's Knowledge, Medicine's
Hope, GENETIcs AND THE HUMAN GENOME PROJECr SYMPOSIUM 12-3 (1995).at 11
(emphasis added).
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needs to be underscored, while the perceived infallibility and
inevitability of genetic diagnoses needs to be de-emphasized and
exposed as untrue. It is unlikely that an absolute diagnosis will ever
be possible. As Proctor concludes:
Even if individuals vary in susceptibility to such agents, it is
probably wishful thinking to imagine that physicians may one day
be able to assure people, from their genetic profiles alone, that they
are or are not at risk for common diseases such as cancer.... It is
misleading to suggest that physicians will ever have this power.6
E. Legal Fallout Due to the Release of Genetic Information in the Public
Domain
This note has focused on how genetic information can be
mishandled. The discussion of genetic discrimination and genetic
determinism have shown that genetic information is highly sensitive
and unlike traditional medical information. An issue that has
received a great deal of attention is whether insurance companies and
employers should be afforded access to genetic information about
clients or employees, current or potential 5  Clearly, genetic risk
assessments could have a dramatic effect on insurance policies and
hiring practices. As early as 1934, Du Pont Company refused
employment to people that admitted a family history of cancer.4 This
is one of the earliest examples of genetic discrimination in U.S.
history.' Society will quickly be forced to evaluate the use of these
information technologies as more financial institutions, such as health
and life insurers, demand greater access to genetic information.
Consider, for example, an episode in February of 1996 involving
Dr. Jonathan Evans, Professor David Nutt, and other scientists at the
University of Bristol's Department of Mental Health.6 By analyzing
the blood samples of a group of people who have attempted suicide,
they were able to identify a common brain enzyme that all patients
seemed to be deficient in: 5-HT.69  In England and Wales,
64. PROCTOR, supra note 5, at 243-44.
65. See Kathy L. Hudson et al., Genetic Discrimination and Health Insurance: An
Urgent Need to Reform, 270 SCIENCE 391, 391 (1995) (a father was unable to obtain
insurance for his four-year-old son, who was fatally diagnosed with a genetic
predisposition); Richard A. Bornstein, Genetic Discrimination, Insurability and
Legislation: A Closing of the Legal Loopholes, 4 J.L. & POL'Y 551,564-68 (1996) (studies
detailing genetic discrimination by health insurers conclude that millions of Americans are
at risk of losing health coverage as a result of carrying genes that give them a
predisposition for certain diseases).
66. PROCTOR, supra note 5, at 221.
67. Id.
68. See Robert Matthews, Scientists Discover that Suicide is in the Blood, SUNDAY
TELEGRAPH, Feb. 4,1996, at 1.
69. Id.
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approximately 10 people commit suicide daily, and the local life
insurance companies are interested in the Bristol development.7 Like
all other chemicals produced by the human body, production of 5-HT
is regulated by a gene, and insurers have encouraged efforts to
develop a genetic test that could diagnose suicidal tendencies."
Professor Nutt insists that the gene does not guarantee that those
carrying it will take their own lives.' He stresses the existence of
several influential factors on suicidal propensity, such as alcohol,
psychological dysfunction, and life stress.73 However, the Association
of British Insurers (ABI) has already said that it will require any life
insurance applicant that has taken a suicide risk test to disclose the
result.7 4 Although ABI stressed that there are no plans for mandatory
screening for their applicants, that guarantee was made before
scientists at the University of Illinois developed a simple blood test to
identify people at high suicide risk based on 5-HT levels." The
researchers claim that a positive result for their test indicates a 55%
probability of suicide.76
The isolation of a "suicide gene" and reliable tests for this
condition represent an example of the kind of detailed information
genetic science can provide. Already, some companies are seeking to
determine premium rates based on genetically predicted health
risks.' What is their reasoning for pursuing such policies? Health
insurance companies claim that access to this information is vital, and
that the current insurance system would collapse if insurers took on
too many high-risk individuals and not enough "good" risk clients.
Conceivably, access to genetic information might facilitate the
efficient spreading of risk.
The Center for Biomedical Ethics at Case Western University
has been investigating the potential involvement of insurance carriers
with sensitive genetic information. Thomas Murray of the Center has
been leading an ELSI sponsored task force charged with studying the
ethical dilemmas associated with release of prospective genetic
information.7" Murray concludes that insurance carriers should be
denied access to genetic information that might indicate a person is
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force investigated the ethics, the science and economics. Our
conclusion was that the only genuine solution is to do away with all
health insurance considerations."80 Murray was cynical of claims by
insurance companies that such information was vital for setting
premiums:
The coming ability to predict who is at genetic risk of disease is
undermining the way we do health insurance in the United States.
Health insurance in the US is built on a Catch-22. Insurers don't
want to cover you for things you're most likely to need.... It
shows the sort of the moral craziness, the moral perversity of the
current system."
Murray's incisive analysis of the American health care system
demonstrates how increasingly advanced GITs will continue to
underscore legal weaknesses in a system that is not prepared to deal
with genetic information. The tension between ethicists, such as
Murray, and insurance companies, such as ABI, demonstrates how
differing parties with special interests will disagree on why access to
genetic information should or should not be granted, and for what
purposes. New policies must be developed which reflect the
involvement of science, commercialism, and the law.
H. Negotiating an Improved Policy for the Future: Prudent
Science and Proactive Law
As demonstrated in part one, genetic research has generated a
number of unique social and legal dilemmas. For example: Who will
decide what is defective and what is not? How will parents decide
whether to abort a fetus whose genes predict a mentally deficient,
moderately painful, or shortened life? Just how far should a society
go in trying to prevent people from passing incurable, hereditary
diseases on to their children? Genetic information is intimate
knowledge, a biography in advance (depending on environmental
cues), not just of the individual but also of his or her relatives. The
genetic information that can be disclosed must be examined carefully,
because we don't yet have the criteria for making these types of
decisions judiciously. Should insurers and employers be allowed to
use genetic tests to deny coverage and jobs to people with "defective"
genes? What of borderline cases where "healthy" can be a very
subjective criteria? What of government projects such as the HGI?
While pursued in the name of science, one side effect of such an
information database is that a definition of what it means to be
genetically normal may be established. We see that social and legal
issues are inextricably intertwined with scientific endeavors.
80. Id.
81. Id.
Although issues such as discrimination certainly existed long
before the study of genetics, GITs could act to amplify and worsen
existing negative social trends without a proper legal framework.
Professor Paul Billings has assembled a host of examples that support
this hypothesis.' He points to the 24 year old woman who was fired
from her job after her employer learned of her genetic predisposition
for Huntington's Disease, a condition that is latent until after 40; or to
the recruits rejected by the Air Force because they were recessive
carriers-but with no symptoms-of sickle cell anemia; or to the case
where a health insurer threatened to cut off medical coverage to a
pregnant woman whose child had been diagnosed with cystic fibrosis
unless the woman agreed to an abortion.' Billings has documented
over 455 cases in which people were denied insurance, health care,
employment, schooling, or the right to adopt children, all on the basis
of a family history of genetic disease." These are the first members of
a new genetic social underclass, one that is being created and shaped
with the help of GITs.
These trends should not be encouraged by another vehicle for
their expression; society cannot allow itself to be seduced by the
immediate benefits of science and technology, and sacrifice long-term
social concerns. Legal steps can be taken to curb negative social
effects. I argue that the unique nature of genetic science and related
technologies has created a condition of uncertainty. The social fallout
from these technologies is poorly understood and unpredictable, and
any experimentation with genetics may cause changes that may only
be fully seen generations from now. The condition of uncertainty
justifies more prudent development and deployment of GITs,
supported by proactive legal measures that take into account the
unique nature of genetic information.
A. More Prudent Research, Development, and Deployment of Genetic
Information Technologies
How do we go about improving the process of research,
development, and implementation? In Philip Sieb's article, it is noted
that "If the uses and ethics of genetic research are to be properly
evaluated, education about this science and scientific literacy generally
must be vastly improved. That presents a clear mandate to schools,
the news media, the religious community and all others who help
shape public knowledge and public opinion."' 5  Shared education
82. See Basu, supra note 58, at 42.
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84. See id.
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May 22,1995, at 11A (emphasis added).
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within and between the scientific and civic community, combined with
increased cultural dialogue, will be key to successfully informing the
public of the limitations and capabilities of GITs.
This could be achieved if government or medical associations
involved in genetic work sponsored public courses on basic genetics.
Or, universities similarly involved with such work could be persuaded
to open such courses to the public. I do not deny that such a policy
implies a responsibility on the part of public and private institutions
to educate the public. But if these institutions are going to produce
technologies that are such potent agents of social change, I believe
that programs for public education must become part of their
operational existence. If citizens are better informed about what
genetics can and can't tell them, genetic information may not seem so
mysterious, and instances of genetic discrimination and premature
fatalism may decrease. Furthermore, better civic education should be
supplemented by strengthening the role of the genetic counselor in
medical decisions. Moreover, a great percentage of the population
would be better served by improving the availability and quality of
educational programs prior to the use of diagnostic techniques. The
benefits of increased and improved civic education are clear.
In order to begin the process, there should be improved dialogue
between policy makers and scientists. Effective cross-disciplinary
programs must be developed to encourage scientists and clinicians to
think through the legal implications of their work and to emphasize
the linkage between science and policy. Integrating an ethics
dialogue into cross-disciplinary education will also bring ethicists in at
an earlier stage of research and development, possibly increasing the
amount of influence they have on GITs at the research stage.
Although improved public and scientific educational programs,
increased dialogue between the general community and the scientific
community, and empowered watchdog groups are good proactive
steps towards formulating improved future policies on GIT
development and deployment, we cannot overlook the fact that GITs
are already in use today. There are numerous legal strategies that can
be adopted to deal with genetic information in the public domain.
B. Proactive Law: Genetic Information Disclosure in the Public Domain
Insurance companies continue to assert that genetic information
able to predict symptoms or susceptibility are imperative to risk
assessment.8 Regardless of whether such disclosure is necessary for
the efficient continuation of insurance policies, experience has shown
that such information can expose subjects to increased premiums,
86. Shore, supra note 32, at 18.
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cancellation of policies, loss of employment, and other negative
effectsY Companies and universities have already developed tests to
diagnose dozens of genetic conditions and are poised to put them into
widespread operation. In a society where many people are
unfamiliar with the particulars of gene theory, this could result in
negative and premature judgments. For example, if people do not
understand that harboring one copy of a "bad" gene does not mean
having a genetic disease, unfounded discrimination and needless
anxiety might result. What can genetic scientists, clinicians, and
researchers who work with human subjects do to minimize these
effects? I advocate using current legal measures as well as promoting
legislation to protect patient privacy and discourage discriminatory
practices.
Psychiatric genetic researchers have the option of obtaining a
"certificate of confidentiality." 9 This certificate prevents insurance
companies, government authorities, and other third parties from
gaining access to sensitive research data.90 Investigators cannot be
forced through legal processes to reveal this information once the
certificate is granted.9 However, the certificate does not mean that
the subject gives up his or her rights of access to information that he
or she has provided.' Nor does it mean that the investigator cannot
report cases of child abuse, and possible suicide or homicide.' These
communications between the patient and investigator are specified in
the informed consent disclosure.94 The certificate of confidentiality is
significant in that it is a readily available legal method to ensure non-
disclosure of genetic information. It should be exercised more
vigorously within the scientific community when questionable
instances of information disclosure arise.
What about the problem of discrimination resulting from the use
of genetic information in the public domain? There is substantial
evidence that suggests genetic discrimination is not only a likely
probability, but a reality. In 1989, the Office of Technology
Assessment's "Medical Monitoring and Screening in the Workplace"
conducted a survey of Fortune 500 companies.95 Survey results
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to assess worker health and/or susceptibility to workplace hazards.96
These figures may seem somewhat encouraging, but are really
deceptive. Further research indicated that "36% of surveyed health
officers assessed the health insurance risk of job applicants and used
this information in their decision to hire an individual."9
Legal measures should be vigorously pursued at both the state
and federal level to prevent irrational genetic discrimination.9s By
late 1998, genetic discrimination legislation had been passed or
drafted in thirty-nine states.? For example, in September of 1991, the
California state legislature passed Assembly Bill 1888 to amend the
California State Civil Rights Act in an attempt to prevent the creation
of a genetically determined underclass.1 ° The bill added genetic
makeup to the list of traits protected from employer discrimination.' 01
Health insurers are also prohibited from declining to cover or
overcharging clients known to carry disease genes." Life and
disability insurance carriers are also prohibited from rejecting
applications on the sole basis of a person's genetic disposition.:
°
Finally, the bill made it illegal for insurers to mandate genetic
testing."' This seems to be a well reasoned legislative
acknowledgment that genes only comprise a fraction of the medical
history of a patient. Although a gene may indicate a person is at risk,
he or she may not develop the condition if it is dependent on
environmental activating cues.05
Although such state legislation is encouraging, it is not sufficient
on its own to prevent genetic discrimination. State laws cannot
regulate self-insured employers exempted by ERISA.1' As almost
two-thirds of employers in the United States are self-insured, state
legislatures are already at a disadvantage in their attempts to curb
genetic discrimination. 07 Further, state laws are more focused on
genetic diagnostic tests, as opposed to the general dissemination of
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genetic information." s Finally, due to the varying nature of state
legislation, state laws are inconsistent and can provide only limited
protection." For these reasons, state legislation must be passed in
conjunction with federal legislation in order to provide an effective
shield against abusive use of genetic information.
The Americans with Disabilities Act of 1990 (ADA) and the
Health Insurance Portability and Accountability Act of 1996
(HIPAA) are the primary federal laws that address genetic
discrimination."0  In 1995, the Equal Employment Opportunity
Commission included "genetic information relating to illness, disease,
or other disorders" in the ADA's definition and protection of
disabilities."' However, it is still difficult to obtain relief under the
ADA because it must be shown that the employer "regarded the
individual as having a genetic defect" and "acted on that basis.
12
Also, recall that a common perception is that genetic conditions tend
to "run in the family." Therefore, if an employer or insurer sees that
a family member is afflicted by a disease with a genetic basis, it may
terminate the policy-holder or employee. This situation is not
protected by the ADA."3 Other uniquely "genetic" situations that
the ADA does not contemplate are the protection of asymptomatic
carriers of recessive genetic mutations, or genetic privacy." Here
too, the ADA falls short of accounting for the unique problems raised
by genetic information, although there is hope for enlightened
interpretation by the courts.
HIPAA, in turn, provides some specific protection against
genetic discrimination by insurers."s It prohibits insurers from using
genetic information to determine eligibility for enrollment or
continuation of insurance coverage. 6 This gives some peace of mind
to employees with genetic conditions who wish to change jobs without
losing health insurance. Unfortunately, HIPAA falls prey to the
same shortcoming as state legislation in that it fails to address
ERISA-exempted self-insured employers and health maintenance
organizations.'' HIPAA also does not address genetic privacy
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concerns resulting from the dissemination of genetic information,
does not regulate genetic testing by insurers, does not address those
who are self-employed, does not prevent the use of genetic
information in risk classification, and does not prohibit employers
from genetically discriminating against people seeking health
insurance." '
Less than 10 years after the Office of Technology Assessment's
survey,"9 genetic discrimination in the workplace has made its way to
the courts. In Norman-Bloodsaw v. Lawrence Berkeley Laboratory,
the blood and urine samples of employees obtained during pre-
employment medical exams were tested for pregnancy, sickle cell
trait, and syphilis without their knowledge or consent.2  The
employees sought relief under Title VII of the Civil Rights Act of
1964 and the ADA.12 ' The California district court dismissed the
ADA and federal privacy claims, finding that they were time-barred,
and, in the alternative, failed on the merits.' The district court
believed that the employees had sufficient notice of the possibility of
these tests because of the highly personal questions unrelated to
employment that appeared on the pre-placement exams.'" Further,
they had consented to a comprehensive medical examination that
included the taking of blood and urine samples.24 As a result of this
notice and consent, the district court wrote that any "additional
incremental intrusion" resulting from the genetic testing wasnegligible."
Perhaps as a portent of future court decisions on genetic cases,
the Court of Appeals for the Ninth Circuit reversed and remanded
the case for trial on the merits.26 The court of appeals found that
there was a material factual dispute regarding whether the employees
should have had reason to believe their employer would perform the
genetic tests without their consent. 7 Further, it was unclear to them
whether performing such tests was consistent with sound medical
practice."2 Defendants' motion for summary judgment, which had
been granted by the district court, was vacated.9  Since the female
employees had been tested for pregnancy, there was a valid Title VII
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claim for sex discrimination.'30 The court also found that the black
employees, who had been targeted for sickle cell trait testing, had
alleged a sufficient cause of action for race discrimination under Title
VII.13' However, the court affirmed the dismissal of the ADA claims
because pre-employment medical examinations of unlimited scope
are permissible, and need not be job-related.'32 Ultimately, the court
concluded that there were valid constitutional claims, even going so
far as to state that "one can think of few subject areas more personal
and more likely to implicate privacy interests than that of one's health
or genetic make-up."'
Legal measures such as the ADA and HIPAA, though imperfect,
suggest that it may be worthwhile to continue to try to work within
the existing political and legal framework to increase awareness of the
issues unique to GITs. However, it is critical that education and
awareness about genetic science and technology be improved. This
will be the key to successful future policies regarding genetic research
and information technologies. Mary Warnock suggests that
"Discussion, explanation, education, and dialogue are needed, within
the context of which people can see what moral issues are at stake."'
' 4
Absent such discussion, there will be no way of achieving the moral
consensus needed to produce judicious legal policies to guide the
development and deployment of genetic applications.
Conclusion
I encourage a policy of proactive legislation; that is, predictable
issues about genetic science should be dealt with before the
technology is developed and deployed. This can be accomplished by
requiring that scientists and lawmakers have consistent contact and
dialogue. Groups like ELSI are certainly a start, but greater efforts
should be made to provide the community of scientists, physicians,
educators, and lawmakers in the federal and state governments with a
competent education in genetic research and information
technologies.'35
Admittedly, the situation at hand does not lend itself to easy
solutions. Nevertheless, informing the public about the capabilities
and limitations of current genetic science, combined with instilling the
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involved professional parties with an interdisciplinary background,
will form the backbone of a competent and intelligent movement to
address the new and exciting issues raised by genetic research and
applications. Working within the existing legal system to establish a
proactive global policy of preventive ethics will facilitate efforts to
conscientiously administer development of GITs.
What new wonders and hazards will this science and technology
bring us in the future? In the realm of genetic research and
increasingly powerful information technologies, it is safe to presume
that we will be surprised by possibilities never before considered. If
history has taught us any lessons about our technological advances, it
is that we are woefully ill-prepared to deal with the fallout from our
technologies (for example, ozone depletion, nuclear waste disposal,
and poorly understood health effects resulting from chemical
manufacture). Charting a judicious course will involve many
considerations including the ones I have outlined, but above all, it will
involve value judgments. These determinations will be less a
questioning of the quality of science involved, but more of a
consensus of how we see risks and benefits. Such trade-offs are the
kind that can-indeed, must-be democratically mediated. Values
require no scientific expertise; any citizen can participate in this
discussion.
Walter Gilbert, a Nobel laureate and a prominent figure in the
realm of biology and scientific research, referred to the human
genome as the "grail of human genetics."'36 By this he meant that the
genome was the key to what makes us Homo sapiens. Unlocking the
secrets of the genome would further our understanding of the limits
and possibilities of our own humanity, and help to better human lives
through practical application. However, the societal and legal
ramifications of genetic science and technology are equally
impressive, and some would say that the continuing, unrestricted and
unregulated advance of genetics is akin to opening a Pandora's Box.
Throughout this note, I have tried to show that GITs can be either a
Holy Grail for science, or a Pandora's Box for society. The case for
continued scientific advancement and discovery is compelling, but
upon closer examination, the possible damage to a society
unprepared for a fast arriving brave new world warrants caution and
justifies a policy of prudent science and proactive legislation. More
than likely, genetics will be both a Holy Grail and a Pandora's Box in
the immediate future, as scientists continue to make incredible new
revelations about our humanity, and policy-makers struggle to frame
those discoveries within our society and legal system.
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